Breaking News

NASA Chooses Boeing, SpaceX to Transport U.S. Astronauts
Tweet TWEET

GenVec to Present at 25th Annual ROTH Conference

               GenVec to Present at 25th Annual ROTH Conference

PR Newswire

GAITHERSBURG, Md., March 12, 2013

GAITHERSBURG, Md., March 12, 2013 /PRNewswire/ --GenVec, Inc. (NASDAQ: GNVC)
announced today that Cindy Collins, GenVec's President and CEO, will present a
Company overview highlighting recent developments starting at 4:00 p.m.
PDT/7:00 p.m. EDT on Tuesday, March 19th at the upcoming 25th Annual ROTH OC
Growth Stock Conference in Laguna Niguel, California.

A webcast of Ms. Collins' presentation will be available both live and on
replay. The presentation will be available via webcast at
http://wsw.com/webcast/roth27/gnvc/. A replay will also be available for 90
days following the live presentation. The live webcast and subsequent archived
replay of GenVec's presentation will also be accessible via the Investors and
Media section of the Company's web site at http://ir.genvec.com under "Events
& Presentations."

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary
technologies to create superior therapeutics and vaccines. A key component of
our strategy is to develop and commercialize our product candidates through
collaborations. GenVec is working with leading companies and organizations
such as Novartis, Merial, and the U.S. Government to support a portfolio of
product programs that address the prevention and treatment of a number of
significant human and animal health concerns. GenVec's development programs
address therapeutic areas such as hearing loss and balance disorders; as well
as vaccines against infectious diseases including respiratory syncytial virus
(RSV), herpes simplex virus (HSV), dengue fever, malaria, and human
immunodeficiency virus (HIV). In the area of animal health we are developing
vaccines against foot-and-mouth disease (FMD). Additional information about
GenVec is available at www.genvec.com and in the Company's various filings
with the Securities and Exchange Commission.

Retail Investor and Media             Institutional Investor Contact:
Contact:
GenVec, Inc.               S.A. Noonan Communications
Douglas J. Swirsky       Susan A. Noonan
(240) 632-5510   (212) 966-3650
dswirsky@genvec.com                  susan@sanoonan.com

SOURCE GenVec, Inc.

Website: http://www.genvec.com
 
Press spacebar to pause and continue. Press esc to stop.